| Patents for A61P 25 - Drugs for disorders of the nervous system (183,225) |
|---|
| 02/13/2013 | CN101868457B (3-hydroxy-4-amino-butan-2-yl) -3- (2-thiazol-2-yl-pyrrolidine-1-carbonyl) benzamide derivatives and related compounds as beta-secretase inhibitors for treating |
| 02/13/2013 | CN101822823B Fibrinogen-420 and new application of active structure domain thereof |
| 02/13/2013 | CN101808999B Quinoline derivatives as 5HT5A receptor antagonists |
| 02/13/2013 | CN101721468B Method for preparing salvianolic acids |
| 02/13/2013 | CN101291939B Thiazolo[4,5-C]pyridine derivatives as mGluR5 receptor antagonists |
| 02/12/2013 | US8372990 Bicyclic tetrahydropyrrole compounds |
| 02/12/2013 | US8372880 Compositions and methods using same for treating amyloid-associated diseases |
| 02/12/2013 | US8372876 Method for improving memory in mammals |
| 02/12/2013 | US8372832 1,4-diaza-bicyclo[3.2.2]nonyl oxadiazolyl compounds and their medical use |
| 02/12/2013 | US8372824 GABA-steroid antagonists and their use for the treatment of CNS disorders |
| 02/12/2013 | US8372431 Pharmaceutical composition comprising licarbazepine acetate |
| 02/12/2013 | US8372401 Human antibodies that bind human TNFα |
| 02/12/2013 | US8372400 Methods of treating disorders using human antibodies that bind human TNFα |
| 02/12/2013 | US8372397 Methods for regulation of stem cells |
| 02/12/2013 | CA2705163C Therapeutic uses of compounds having combined sert, 5-ht3 and 5-ht1a activity |
| 02/12/2013 | CA2696705C New benzothiadiazepine derivatives, preparation method thereof and pharmaceutical compositions containing same |
| 02/12/2013 | CA2628750C 4-oxadiazolyl-piperidine compounds and use thereof |
| 02/12/2013 | CA2601222C Once-a-day oxycodone formulations |
| 02/12/2013 | CA2570155C 3-(heteroaryl-oxy)-2-alkyl-1-aza-bicycloalkyl derivatives as alpha.7-nachr ligands for the treatment of cns diseases |
| 02/12/2013 | CA2498936C Structurally rigid dopamine d3 receptor selective ligands and process for making them |
| 02/12/2013 | CA2468892C Vitamin d analogues |
| 02/12/2013 | CA2416988C Leucine-based motif and clostridial neurotoxins |
| 02/07/2013 | WO2013020136A2 Treatment of traumatic brain injury |
| 02/07/2013 | WO2013019938A1 Pyridazine derivatives as eaat2 activators |
| 02/07/2013 | WO2013018883A1 Cancer treatment and/or prevention drug composition |
| 02/07/2013 | WO2013018733A1 1,5-naphthyridine derivative or salt thereof |
| 02/07/2013 | WO2013018695A1 Heterocyclic compound |
| 02/07/2013 | WO2013018374A1 Ketone derivative and drug containing same |
| 02/07/2013 | WO2013018372A1 Amide derivative and drug containing same |
| 02/07/2013 | WO2013018371A1 Biaryl ester derivative and drug containing same |
| 02/07/2013 | WO2013018091A1 Particles for the treatment of neurodegenerative diseases |
| 02/07/2013 | WO2013018008A1 Basic alpha lipoic acid solution and its uses |
| 02/07/2013 | WO2013017974A1 Compositions and methods for the treatment of neuromuscular disorders and neurodegenerative diseases |
| 02/07/2013 | WO2013017657A1 Phenyl-3-aza-bicyclo[3.1.0]hex-3-yl-methanones and the use thereof as medicament |
| 02/07/2013 | WO2013017619A1 Diphenyl substituted cyclohexane derivatives, useful as modulators of the estrogen receptors beta |
| 02/07/2013 | WO2013017233A1 Intrathecal or epidural administration of 3-[(1s,2s)-3-(dimethylamino)-1-ethyl-2-methylpropyl]phenol |
| 02/07/2013 | WO2013017136A1 Treatment of cognitive impairment |
| 02/07/2013 | WO2013017071A1 Alicyclic[c] benzopyrone derivatives and uses thereof |
| 02/07/2013 | WO2013017068A1 Substituted benzopyrone derivative and use thereof |
| 02/07/2013 | WO2013017053A1 Composite vaccine for preventing and treating alzheimer's disease and preparation method therefor |
| 02/07/2013 | US20130036481 Use of perlecan domain v in treating amyloidogenic disease |
| 02/07/2013 | US20130035393 Method for treating schizophrenia |
| 02/07/2013 | US20130035392 Selective inhibition of the membrane attack complex of complement and C3 convertase by low molecular weight components of the aurin tricarboxylic acid synthetic complex |
| 02/07/2013 | US20130035390 Treatment of multiple sclerosis |
| 02/07/2013 | US20130035388 Selective inhibition of the membrane attack complex of complement by low molecular weight components of the aurin tricarboxylic acid synthetic complex |
| 02/07/2013 | US20130035385 Orally dispersible tablet |
| 02/07/2013 | US20130035384 Orally dispersible tablet |
| 02/07/2013 | US20130035368 Oligonucleotide compounds comprising non-nucleotide overhangs |
| 02/07/2013 | US20130035364 Benzylidene-indolinone compounds and their medical use |
| 02/07/2013 | US20130035363 Thalidomide Analogs |
| 02/07/2013 | US20130035358 Bis Aromatic Compounds for Use as LTC4 Synthase Inhibitors |
| 02/07/2013 | US20130035354 Aryl pyridine as aldosterone synthase inhibitors |
| 02/07/2013 | US20130035352 Gaba conjugates and methods of use thereof |
| 02/07/2013 | US20130035347 Aromatic bycyclic derivatives as cxcr4 receptor modulators |
| 02/07/2013 | US20130035346 Amide derivatives bearing a cyclopropylaminoacarbonyl substituent useful as cytokine inhibitors |
| 02/07/2013 | US20130035345 Solid dispersion formulations and methods of use thereof |
| 02/07/2013 | US20130035342 Compound Suitable for the Treatment of Synucleopathies |
| 02/07/2013 | US20130035339 Apoptosis signal-regulating kinase inhibitors |
| 02/07/2013 | US20130035337 Fused bicyclic heteroaryl derivative |
| 02/07/2013 | US20130035335 8-ethyl-6-(aryl)pyrido[2,3-d]pyrimidin-7(8h)-ones for the treatment of cns disorders |
| 02/07/2013 | US20130035333 Use of cinnabarinic acid as a modulator of immune responses in autoimmune disorders |
| 02/07/2013 | US20130035332 Substituted 1,3-Benzothiazol-2(3H)-Ones and [1,3]Thiazolo[5,4-B]Pyridin-2(IH)-Ones as Positive Allosteric Modulators of MGLUR2 |
| 02/07/2013 | US20130035327 Modulators of ATP-Binding Cassette Transporters |
| 02/07/2013 | US20130035326 Biaryl compounds and methods of use thereof |
| 02/07/2013 | US20130035323 Aminochromane, aminothiochromane and amino-1,2,3,4-tetrahydroquinoline derivatives, pharmaceutical compositions containing them, and their use in therapy |
| 02/07/2013 | US20130035311 Prochelators for inhibiting metal-promoted oxidative stress |
| 02/07/2013 | US20130035310 Piperidine and Piperazine Phenyl Sulfonamides as Modulators of Ion Channels |
| 02/07/2013 | US20130035305 Use of an active ingredient combination that contains hydroxystilbene for preventing and/or treating diseases |
| 02/07/2013 | US20130035302 Use of yessotoxin and analogues and derivatives thereof for treating and/or preventing neurodegenerative diseases linked to tau and beta amyloid |
| 02/07/2013 | US20130035294 Neuromedin and FN-38 Peptides for Psychotic Diseases |
| 02/07/2013 | US20130035293 Compositions and methods for modulating dopamine neurotransmission |
| 02/07/2013 | US20130035292 NMDA Receptors Modulators and Uses Thereof |
| 02/07/2013 | US20130035281 Pharmaceutical composition, methods for treating and uses thereof |
| 02/07/2013 | US20130034604 Extended release formulations of desvenlafaxine base |
| 02/07/2013 | US20130034599 Synthetic nanostructures including nucleic acids and/or other entities |
| 02/07/2013 | US20130034595 Local administration of gallium compositions to treat pain |
| 02/07/2013 | US20130034590 Delivery of Hydrophilic Drugs |
| 02/07/2013 | US20130034572 Compositions and methods for brain delivery of analgesic peptides |
| 02/07/2013 | US20130034569 Il-18 receptor antigen binding proteins |
| 02/07/2013 | US20130034545 Treatment of traumatic brain injury using antibodies to lysophosphatidic acid |
| 02/07/2013 | US20130034537 Simultaneous co-treatment of physical and mental symptoms related to severe mental disorders by a specially fermented soy formulation (fsww08) |
| 02/07/2013 | US20130034530 Dietary Supplement Cognitive Support System |
| 02/07/2013 | US20130034503 Preventing or reducing drug abuse and overdose events |
| 02/07/2013 | CA2844030A1 Pharmaceutical composition for treatment and/or prophylaxis of cancer |
| 02/07/2013 | CA2843805A1 Phenyl-3-aza-bicyclo[3.1.0]hex-3-yl-methanones and the use thereof as medicament |
| 02/07/2013 | CA2843436A1 Novel 17.beta.-heteroaryl-substituted steroids as modulators of gaba a receptors |
| 02/07/2013 | CA2842394A1 Diphenyl substituted cyclohexane derivatives, useful as modulators of the estrogen receptors beta |
| 02/07/2013 | CA2839122A1 Intrathecal or epidural administration of 3-[(1s,2s)-3-(dimethylamino)-1-ethyl-2-methylpropyl]phenol |
| 02/06/2013 | EP2554542A1 Phenylalanine derivative salt crystal |
| 02/06/2013 | EP2554541A1 Therapeutic agent or prophylactic agent for fibromyalgia |
| 02/06/2013 | EP2554532A1 Diphenyl substituted cyclohexane derivatives, useful as modulators of the estrogen receptors beta |
| 02/06/2013 | EP2554180A1 Compounds for use in the treatment of diseases based on the expression of toxic transcripts |
| 02/06/2013 | EP2554178A1 Expression modulator for clock gene period |
| 02/06/2013 | EP2554177A1 Expression modulator for clock gene bmal |
| 02/06/2013 | EP2554175A1 Composition for treatment of damaged part |
| 02/06/2013 | EP2554164A1 Pharmaceutical formulation based on ibuprofen and codeine having having improved stability |
| 02/06/2013 | EP2554163A1 Neurodegenerative disease therapeutic agent |
| 02/06/2013 | EP2554162A1 Use of KCNQ-Openers for Treating or Reducing the Symptoms of Schizophrenia |
| 02/06/2013 | EP2554058A1 Functional food supplement intended, in particular, for nutrition and for prevention and improvement in cases of neurological alterations, neurodegenerative alterations or cognitive disorders |
| 02/06/2013 | EP2554057A1 Enteral or oral food product intended, in particular, for nutrition and for the prevention and improvement of neurological alterations, neurodegenerative alterations or cognitive disorders |